Chiron Corporation

Novartis Vaccines & Diagnostics, Gmbh

Nordisk Gentofte

Novo Nordisk A/s

George Kuo

Michael Houghton

Qui-Lim Choo

Pablo D Valenzuela

Kent B Thudium

Frank R Masiarz

John Andrew Hall

Frank I Marcus

Martha Truett

Robert O Ralston

Barbara A Gervase

Kim M Berger

Mirella Ezban Rasmussen

Philip J Barr

David Y Chien

Jennifer M Favaloro

Michael S Urdea

Rae Lyn Burke

Jang Hyun Han

Amy J Weiner

Janice A Kolberg

Bruce D Irvine

Carol A Pachl

Daniel Caput

Oui-Lim Choo

A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBH agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.

NANBV diagnostics and vaccines

Methods and compositions are provided for recombinant DNA production of Factor VIIIC and truncated derivatives thereof. Based on amino acid sequences, probes are developed for isolating messenger RNA, cDNA and/or chromosomal DNA encoding for Factor VIIIC. The Factor VIIIC gene in its entirety, a fragment thereof, or a cDNA is then used for expression of Factor VIIIC in a host. The bacteriophage &#x3bb;FVIII23D containing the 14.43 kb EcoRI fragment was deposited at the A.T.C.C. on Jan. 4, 1984 and given Accession No. 40094. Also, the vector pSVF8-200 was deposited at the A.T.C.C. on Jul. 17, 1985 and given Accession No. 40190.

Factor VIII:C nucleic acid molecules

Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.

Antibodies to hepatitis C virus asialoglycoproteins

The claimed invention provides methods of detecting and typing HCV using nucleic acid molecules encoding type specific and type-cluster specific epitopes. The nucleic acid molecules flanking regions encoding type specific or type cluster specific epitopes are useful in priming the polymerase chain reaction to determine the genotype an HCV isolate.

Methods of typing hepatitis C virus and reagents for use therein

The present invention provides methods and compositions for use therein for typing hepatitis C viruses.

Combinations of HCV antigens that have a broader range of immunological reactivity than any single HCV antigen. The combinations consist of an antigen from the C domain of the HCV polyprotein, and at least one additional HCV antigen from either the NS3 domain, the NS4 domain, the S domain, or the NS5 domain, and are in the form of a fusion protein, a simple physical mixture, or the individual antigens commonly bound to a solid matrix.

Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies

Hepatitis C virus asialoglycoproteins

Antibody compositions to HCV and uses thereof

Cell culture systems for HCV

NANBV diagnostics: polynucleotides useful for screening for hepatitis C

The claimed invention provides methods of detecting and typing HCV using type specific and type-cluster specific epitopes. The claimed invention also provides peptides having type specific and type-cluster specific epitopes.

NANBV Diagnostics and vaccines

Growing community of inventors

San Francisco, CA, United States of America

George Kuo